FDA Approves First COVID-19 Treatment for Young Children
The press release was published on the U.S. Food and Drug Administration website: On Apr. 26, 2022, the U.S. Food
Tag: Dexolve
Sulfobutylation of Beta-Cyclodextrin Enhances the Complex Formation with Mitragynine: An NMR and Chiroptical Study
Mitragynine (MTR), the main indole alkaloid of the well-known plant kratom (Mitragyna speciosa) is a partial agonist on the opioid
Use of Antivirals in SARS-CoV-2 Infection. Critical Review of the Role of Remdesivir
The aim of this report is to review the literature and shed light on the uncertainties surrounding the use of
CycloLab awarded by 2021 Innovation Grand Prize
The Hungarian Association of Innovation awarded CycloLab with this prestigious prize due to its meaningful and very profitable innovation concerning
Effect of Sulfobutylether-β-CD on Silver Nanoparticles Synthesis and Stability in aqueous solution
An innovative application of sulfobutylether-β-CD (SBE-βCD) regarding the preparation of spherical and monodispersed silver nanoparticles (AgNPs) was recently described [1].
FDA Approves Veklury® (Remdesivir) for the Treatment of Non-Hospitalized Patients at High Risk for COVID-19 Disease Progression
— Approval Based on Phase 3 Data Showing Veklury Significantly Reduced Risk of Hospitalization By 87% Compared with Placebo —
Voriconazole–Cyclodextrin Supramolecular Ternary Complex-Loaded Ocular Films
Prof. Lewis’ group used the multicomponent complex formation of CDs with hydroxy acids to improve the pharmacokinetic of voriconazole. Fungal
Remdesivir interactions with sulfobutylether-b-cyclodextrins: A case study using selected substitution patterns
A structural and thermodynamic analysis for the interaction between SBECD and neutral or protonated remdesivir has been performed using multiple
Marinus Announces FDA Acceptance for Filing and Priority Review of NDA for SBECD-enabled Ganaxolone in CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. , a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, announced that
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-07 for the Acute Treatment of Migraine
Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced